Brief Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusionto slowly introduce/give fluid into a vein to participants with relapsed or refractory multiple myeloma (R/R MM).
Intervention / Treatment
- Drug: Cevostamab
- Drug: Tocilizumab
Inclusion Criteria
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Participants must have relapsed or refractory (R/R) multiple myeloma (MM) for which no established therapy for MM is appropriate and available or be intolerant to those established therapies
- Adverse events from prior anti-cancer therapy resolved to Gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells < or = 1, except any grade alopeciathe partial or complete absence of hair from areas of the body where it normally grows; baldness and/or peripheral sensory or motor neuropathy which must have resolved to Grade < or = 2
- Measurable disease defined by laboratory test results
- Female participants of childbearing age must agree to remain abstinent or use reliable contraceptive methods during the treatment period, and at least 5 months after last dosethe amount of medication taken of study drug. Women must refrain from breastfeeding during the same period.
- Male participants must agree to refrain from donating sperm, to abstain or use a condom during the treatment period, and for at least 2 months after the last dose of tocilizumab (if applicable).